{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T13:19:22Z","timestamp":1782998362681,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"crossref","award":["SCUT-2015zz051"],"award-info":[{"award-number":["SCUT-2015zz051"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ejps.2017.03.048","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T20:52:58Z","timestamp":1491425578000},"page":"212-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Effect of oxymatrine HSPC liposomes on improving bioavailability, liver target distribution and hepatoprotective activity of oxymatrine"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5430-4195","authenticated-orcid":false,"given":"Meifeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2017.03.048_bb0005","first-page":"47","article-title":"Clinical efficacy of kurorinone in the treatment of chronic hepatitis B","volume":"18","author":"Cai","year":"1997","journal-title":"Acad. J. Sec. Mil. Med. Univ."},{"issue":"31","key":"10.1016\/j.ejps.2017.03.048_bb0010","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.3748\/wjg.v18.i31.4199","article-title":"OMT liposome attenuates hepatic fibrosis via targeting hepatic stellate cells","volume":"18","author":"Chai","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejps.2017.03.048_bb0015","first-page":"216","article-title":"Progress in mechanism of father-infant dissemination of hepatitis B virus","volume":"36","author":"Dai","year":"2015","journal-title":"J. Jilin. Med. Coll"},{"key":"10.1016\/j.ejps.2017.03.048_bb0020","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1046\/j.1440-1746.2002.02885.x","article-title":"Effects of OMT on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice: a study on the anti-hepatitis B virus mechanism of OMT","volume":"17","author":"Dong","year":"2002","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejps.2017.03.048_bb0025","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/03639040600760556","article-title":"Studies on the encapsulation of OMT into liposomes by ethanol injection and pH gradient method","volume":"32","author":"Du","year":"2006","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"1","key":"10.1016\/j.ejps.2017.03.048_bb0030","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1186\/1476-9255-9-16","article-title":"Hepatoprotective effect of MT salvianolic acid B salt on carbon tetrachloride-induced hepatic fibrosis","volume":"9","author":"Gao","year":"2012","journal-title":"J. Inflamm."},{"issue":"Issue 1","key":"10.1016\/j.ejps.2017.03.048_bb0035","first-page":"4387","article-title":"Thermosensitive liposomal drug delivery systems: state of the art review","author":"Kneidl","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2017.03.048_bb0040","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.2147\/IJN.S105035","article-title":"Increased cutaneous wound healing effect of biodegradable liposomes containing madecassoside: preparation optimization, in vitro dermal permeation, and in vivo bioevaluation","volume":"11","author":"Li","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2017.03.048_bb0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0378-8741(94)90084-1","article-title":"The effect of Chinese hepatoprotective medicines on experimental liver injury in mice","volume":"42","author":"Liu","year":"1994","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejps.2017.03.048_bb0050","first-page":"74","article-title":"Recommendations for prevention and treatment and studies of viral and chronic hepatitis","volume":"82","author":"Liu","year":"2002","journal-title":"Natl. Med. J."},{"key":"10.1016\/j.ejps.2017.03.048_bb0055","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.3748\/wjg.v9.i11.2480","article-title":"OMT therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial","volume":"9","author":"Lu","year":"2003","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejps.2017.03.048_bb0060","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3748\/wjg.v10.i8.1176","article-title":"Inhibitory effect of OMT on serum hepatitis B virus DNA in HBV transgenic mice","volume":"10","author":"Lu","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejps.2017.03.048_bb0065","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.3748\/wjg.v10.i22.3269","article-title":"Capsule OMT in treatment of hepatic fibrosis due to chronic viral hepatitis: a randomized, double blind, placebo-controlled, multicenter clinical study","volume":"10","author":"Mao","year":"2004","journal-title":"World J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.ejps.2017.03.048_bb0070","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1023\/A:1015924124180","article-title":"Nebulization of liposomes. I. Effects of lipid composition","volume":"7","author":"Niven","year":"1990","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2017.03.048_bb0075","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2174\/1381612822666151112152733","article-title":"Antiviral natural products against chronic hepatitis B: recent developments","volume":"22","author":"Parvez","year":"2016","journal-title":"Curr. Pharm. Design."},{"issue":"1\u20133","key":"10.1016\/j.ejps.2017.03.048_bb0080","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0378-5173(93)90389-W","article-title":"Liposomes obtained by the ethanol injection method","volume":"95","author":"Pons","year":"1993","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.03.048_bb0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF02976506","article-title":"The structure of kushenol M from Sophora flavescens","volume":"18","author":"Ryu","year":"1995","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ejps.2017.03.048_bb0090","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0163-7827(00)00020-5","article-title":"The role of hepatocytes in the clearance of liposomes from the blood circulation","volume":"40","author":"Scherphof","year":"2001","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ejps.2017.03.048_bb0095","series-title":"Modern of Pharmacology","author":"Wang","year":"1997"},{"key":"10.1016\/j.ejps.2017.03.048_bb0100","first-page":"301","article-title":"Pharmacokinetic study of OMT injection in Chinese healthy volunteers","volume":"19","author":"Wang","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.03.048_bb0105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.antiviral.2011.01.005","article-title":"OMT inhibits hepatitis B infection with an advantage of overcoming drug-resistance","volume":"89","author":"Wang","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejps.2017.03.048_bb0110","author":"World Health Organization"},{"key":"10.1016\/j.ejps.2017.03.048_bb0115","first-page":"343","article-title":"Antifungal substances from Sophora flavescens","volume":"43","author":"Yagi","year":"1989","journal-title":"Shoyakugaku Zasshi"},{"key":"10.1016\/j.ejps.2017.03.048_bb0120","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejps.2013.11.017","article-title":"Targeted delivery of the RGD-labeled biodegradable polymersomes loaded with the hydrophilic drug OMT on cultured hepatic stellate cells and liver fibrosis in rats","volume":"52","author":"Yang","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"17","key":"10.1016\/j.ejps.2017.03.048_bb0125","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1111\/bph.13209","article-title":"Identification of MT as a promising novel drug for hepatic steatosis and glucose intolerance with HSP72 as an upstream target","volume":"172","author":"Zeng","year":"2015","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.ejps.2017.03.048_bb0130","first-page":"183","article-title":"Antifibrotic effects of MT on in vitro and in vivo models of liver fibrosis in rats","volume":"22","author":"Zhang","year":"2001","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.ejps.2017.03.048_bb0135","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1208\/s12249-014-0086-y","article-title":"Liposomal OMT in hepatic fibrosis treatment: formulation, in vitro and in vivo assessment","volume":"15","author":"Zhang","year":"2014","journal-title":"AAPS PharmSciTech"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717301859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717301859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T19:39:23Z","timestamp":1589744363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717301859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":27,"alternative-id":["S0928098717301859"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.03.048","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of oxymatrine HSPC liposomes on improving bioavailability, liver target distribution and hepatoprotective activity of oxymatrine","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.03.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}